CA-VERIMATRIX/TELESTREAM
29.8.2022 17:46:43 CEST | Business Wire | Press release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, and Telestream, a global leader in video quality monitoring, test and measurement solutions, today announced that Surveyor ABR Active, Telestream iQ's ABR streaming QoE and QoS monitoring technology, is integrated within Verimatrix StreamkeeperSM Multi-DRM, available in the Verimatrix Secure Delivery Platform.
Through the integration, Telestream further builds on its innovative offerings for the digital video industry which include workflow automation, media processing, and quality monitoring solutions for the production and distribution of video. Telestream’s integration with Streamkeeper Multi-DRM allows users to capitalize on Verimatrix’ s cost-effective cloud-based solution while maintaining full visibility into video and audio content quality. Together, Verimatrix and Telestream accelerate time to market while maintaining service visibility for operators.
Verimatrix Streamkeeper Multi-DRM delivers studio endorsed best practices for content protection, with meticulous focus on ensuring superior video viewer experiences. As a suite of adaptive cybersecurity technologies that include and go beyond DRM, Streamkeeper allows video service providers to manage revenue risk in a world of continuously changing threats from video piracy and cybercriminals.
Telestream’s video quality monitoring solutions are trusted worldwide to provide video service assurance and operational visibility for valuable live and on-demand video services. As digital workflows move to the cloud, Telestream’s pedigree monitoring solutions, coupled with Verimatrix, means those planning to migrate their video workflows to the cloud will have equal or better operational visibility than ever before.
Telestream iQ provides full video and audio quality analysis both at the transcoding location and post CDN for live and on-demand services, allowing operators full visibility into content quality issues – even with full security encryption in place. Telestream iQ’s solutions ensure that audio and video quality errors such as compression errors, pixelization, black screen, still frame, and audio loudness are caught early, allowing rapid time-to-resolution and the ongoing protection of revenue and reputation.
“A longstanding alliance partner of Verimatrix, Telestream is proud to be one of its first partners to integrate with Streamkeeper Multi-DRM,” said Joel Daly, vice president of product management at Telestream. “Together we provide a solution that builds security, service assurance and operational visibility into cloud video workflows, de-risking the migration to cloud for global content and video service providers.”
“We’re extremely pleased to work with such highly-recognized industry visionaries such as Telestream as we continue to widen the number the number of integrated solutions available within Verimatrix Streamkeeper Multi-DRM,” said Sebastian Braun, senior director of product management at Verimatrix. “We’re pleased to continue our acceleration of additive value adoption through a global network of trusted partners.”
Verimatrix Streamkeeper is available in multiple tiers and includes features such as a real-time performance dashboard, on-call support integrations and alerts, individual device risk scoring and anti-piracy countermeasures.
Surveyor ABR Active provides essential insights that enable content owners and streaming service providers to manage critical issues relate to Quality of Service (QoS) and Quality of Experience (QoE) for live and on-demand services. It acts as the most critical viewer, measuring video flows for every bitrate variant and format.
For more information about Verimatrix Streamkeeper, visit: www.verimatrix.com/products/streamkeeper.
About Telestream
For nearly 25 years, Telestream® has been at the forefront of innovation in the digital video industry. The company develops products for media processing and workflow orchestration, live capture, streaming, production, video quality assurance, virtual events and video hosting, content management, and video and audio test solutions. Available on premises or in the cloud as well as in hybrid combinations, Telestream solutions make it possible to reliably get video content to any audience, regardless of how it is created, distributed or viewed. Telestream is privately held with corporate headquarters located in Nevada City, California and Westwood, Massachusetts.
For company and product information, visit www.Telestream.net.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005371/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom